Abstract
The main aim of this study was to investigate the potential role of levan polysaccharide in developing polysaccharide-based anticancer therapeutics. Moreover, by periodate oxidation, chemically modified forms of levan harboring increasing amounts of aldehyde groups were obtained and characterized. All the samples were found to be biocompatible when treated with the mouse fibroblast cell line L929. Anti-cancer activities of levan and its derivatives were investigated in A549 (human lung adenocarcinoma), HepG2/C3A (human liver hepatocellular carcinoma), AGS (human gastric adenocarcinoma), and MCF-7 (human breast adenocarcinoma) cell lines and were found to depend on the dose as well as on the cell type. The observed decrease in cancer cell viability was shown to be due to apoptosis via luminogenic-based caspase-3/7 activity assay. This study established the high potential of these levan-based polymers in developing polysaccharide-based nanocarrier systems for anti-cancer drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
